The founders share the view that there is an urgent need to collaborate across the pharmaceutical supply chain and while there is much discussion in the pharma community today about sustainability and climate impact, substantial change among supply chain partners and manufacturers is not happening fast enough to reduce the emissions footprint. This is what the Alliance to Zero is committed to changing. The following companies are among the founding members: Datwyler, Harro Höfliger, HealthBeacon, Körber Pharma, Schott, Schreiner MediPharm, Sharp, Ypsomed.
“Membership in the Alliance to Zero fits perfectly with our sustainability strategy, which includes striving for climate neutrality at all our sites worldwide by 2030”, says Datwyler CEO Dirk Lambrecht.
In order to develop solutions that will have broad acceptance and a true positive impact on the pharmaceutical industry, the alliance recognises the need for deep and proactive collaboration across traditional company boundaries. The founding companies of the alliance represent key parts of the pharma supply chain, including component suppliers, machine suppliers and assembly/manufacturing service providers, as well as those involved in primary packaging to final device assembly and even collection after use.
“The formation of this alliance is the first step in a challenging but urgent journey that our member organisations have committed themselves to,” says Sebastian Gerner, president of the Alliance to Zero. “Enabling the launch of net zero pharmaceutical products in regulated markets will require companies like ours to transform our operations, products, services, logistics, innovations and investments”, continued Sebastian. “Our combined effort and our shared responsibility to ensure a real and lasting change is at the heart of the Alliance’s mission.”
The alliance has begun development of a roadmap describing what a net zero emission concept for pharmaceutical manufacturing and supply chain would look like and the steps necessary to achieve it. This foundational work also includes agreement on harmonized language and principles for the assessment and control of the total emission footprint for the final pharmaceutical products, as well as the company-specific responsibilities.
The Alliance to Zero intends to involve, connect and coordinate suppliers, pharmaceutical companies, manufacturers and service providers along the supply chain and engage with academia and non-profit organisations with similar aims.
Further information including their manifesto was published today on the Alliance to Zero website www.alliancetozero.com.
Datwyler – leading provider of high-quality, system-critical elastomer components
Datwyler is focusing on high-quality, system-critical elastomer components and has leading positions in attractive global markets such as healthcare, mobility and food & beverage. With its recognized core competencies and technological leadership, the company delivers added value to customers in the markets served. Datwyler concentrates on markets that offer opportunities to create more value and sustain profitable growth. With more than 20 operating companies, sales in over 100 countries and more than 7’000 employees Datwyler, headquartered in Switzerland, generates annual sales of more than CHF 1’000 million (incl. online distributor Reichelt). The company has been listed on the SIX Swiss Exchange since 1986 (security no. 3048677).
Dätwyler Holding AG
Telefon: +41 (41) 8751304
Telefax: +41 (41) 8751205
Head Corporate Communications
Telefon: +41 (41) 87519-00
Fax: +41 (41) 87512-05